**11. Perspectives upon the commercial production of medicines and pharmaceutical proteins in molecular farming**

The development stages and subsequent commercialization of the products is the subject of consideration in the second phase of clinical trials. A number of small biotechnology compa‐ nies have aimed to commercialize the antibodies produced in plants. It has been estimated that the increasing annual need for secretory IgA will be 13%, and a rate of \$25 billion was predicted as the annual income of producing IgA in crops. While there have been great advances in the field of biomedicine production in plants on large scales, fundamental studies are demanded to pave the way for the commercialization of these products. The present problems include the difficulty of low yield of protein, the possibility of harmful effects on the function/ performance of proteins due to the differences in glycosylation patterns, and the severe potential impact of expressing plants of biomedicine plants on the environment (e.g., concerns upon genetic limitations) [74].
